dc.contributor.author | Jayson, GC | |
dc.contributor.author | Zhou, C | |
dc.contributor.author | Backen, A | |
dc.contributor.author | Horsley, L | |
dc.contributor.author | Marti-Marti, K | |
dc.contributor.author | Shaw, D | |
dc.contributor.author | Mescallado, N | |
dc.contributor.author | Clamp, A | |
dc.contributor.author | Saunders, MP | |
dc.contributor.author | Valle, JW | |
dc.contributor.author | Mullamitha, S | |
dc.contributor.author | Braun, M | |
dc.contributor.author | Hasan, J | |
dc.contributor.author | McEntee, D | |
dc.contributor.author | Simpson, K | |
dc.contributor.author | Little, RA | |
dc.contributor.author | Watson, Y | |
dc.contributor.author | Cheung, S | |
dc.contributor.author | Roberts, C | |
dc.contributor.author | Ashcroft, L | |
dc.contributor.author | Manoharan, P | |
dc.contributor.author | Scherer, SJ | |
dc.contributor.author | Del Puerto, O | |
dc.contributor.author | Jackson, A | |
dc.contributor.author | O'Connor, JPB | |
dc.contributor.author | Parker, GJM | |
dc.contributor.author | Dive, C | |
dc.date.accessioned | 2020-08-12T14:46:00Z | |
dc.date.issued | 2018-11-07 | |
dc.identifier.citation | Nature communications, 2018, 9 (1), pp. 4672 - ? | |
dc.identifier.issn | 2041-1723 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/3941 | |
dc.identifier.eissn | 2041-1723 | |
dc.identifier.doi | 10.1038/s41467-018-07174-1 | |
dc.description.abstract | Oncological use of anti-angiogenic VEGF inhibitors has been limited by the lack of informative biomarkers. Previously we reported circulating Tie2 as a vascular response biomarker for bevacizumab-treated ovarian cancer patients. Using advanced MRI and circulating biomarkers we have extended these findings in metastatic colorectal cancer (n = 70). Bevacizumab (10 mg/kg) was administered to elicit a biomarker response, followed by FOLFOX6-bevacizumab until disease progression. Bevacizumab induced a correlation between Tie2 and the tumor vascular imaging biomarker, Ktrans (R:-0.21 to 0.47) implying that Tie2 originated from the tumor vasculature. Tie2 trajectories were independently associated with pre-treatment tumor vascular characteristics, tumor response, progression free survival (HR for progression = 3.01, p = 0.00014; median PFS 248 vs. 348 days p = 0.0008) and the modeling of progressive disease (p < 0.0001), suggesting that Tie2 should be monitored clinically to optimize VEGF inhibitor use. A vascular response is defined as a 30% reduction in Tie2; vascular progression as a 40% increase in Tie2 above the nadir. Tie2 is the first, validated, tumor vascular response biomarker for VEGFi. | |
dc.format | Electronic | |
dc.format.extent | 4672 - ? | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | NATURE PUBLISHING GROUP | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.subject | Humans | |
dc.subject | Colorectal Neoplasms | |
dc.subject | Disease Progression | |
dc.subject | Neovascularization, Pathologic | |
dc.subject | Receptor, TIE-2 | |
dc.subject | Angiogenesis Inhibitors | |
dc.subject | Angiopoietin-2 | |
dc.subject | Vascular Endothelial Growth Factor A | |
dc.subject | Prognosis | |
dc.subject | Disease-Free Survival | |
dc.subject | Models, Biological | |
dc.subject | Adult | |
dc.subject | Aged | |
dc.subject | Middle Aged | |
dc.subject | Female | |
dc.subject | Male | |
dc.subject | Kaplan-Meier Estimate | |
dc.subject | Biomarkers, Tumor | |
dc.subject | Bevacizumab | |
dc.title | Plasma Tie2 is a tumor vascular response biomarker for VEGF inhibitors in metastatic colorectal cancer. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2018-10-04 | |
rioxxterms.versionofrecord | 10.1038/s41467-018-07174-1 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.licenseref.startdate | 2018-11-07 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Nature communications | |
pubs.issue | 1 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Quantitative Biomedical Imaging | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Quantitative Biomedical Imaging | |
pubs.publication-status | Published | |
pubs.volume | 9 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Quantitative Biomedical Imaging | |
dc.contributor.icrauthor | O'Connor, James Patrick | |